Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma Journal Article


Authors: Ady, J. W.; Johnsen, C.; Mojica, K.; Heffner, J.; Love, D.; Pugalenthi, A.; Belin, L. J.; Chen, N. G.; Yu, Y. A.; Szalay, A. A.; Fong, Y.
Article Title: Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma
Abstract: Background Hepatocellular carcinoma (HCC) commonly presents at a late stage when surgery is no longer a curative option. As such, novel therapies for advanced HCC are needed. Oncolytic viruses are a viable option for cancer therapy owing to their ability to specifically infect, replicate within, and kill cancer cells. In this study, we have investigated the ability of GLV-2b372, a novel light-emitting recombinant vaccinia virus derived from a wild-type Lister strain, to kill HCC. Methods Four human HCC cell lines were assayed in vitro for infectivity and cytotoxicity. Viral replication was quantified via standard viral plaque assays. Flank HCC xenografts generated in athymic nude mice were treated with intratumoral GLV-2b372 to assess for tumor growth inhibition and viral biodistribution. Results Infectivity occurred in a time- and concentration-dependent manner with 70% cell death in all cell lines by day 5. All cell lines supported efficient viral replication. At 25 days after infection, flank tumor volumes decreased by 50% whereas controls increased by 400%. Tumor tissue demonstrated substantial GLV-2b372 infection at 24 hours, 48 hours, and 2 weeks. Conclusion We demonstrate that GLV-2b372 efficiently kills human HCC in vitro and in vivo and is a viable treatment option for patients with HCC. © 2015 Elsevier Inc. All rights reserved.
Keywords: controlled study; human cell; liver cell carcinoma; nonhuman; mouse; animal tissue; cell death; tumor volume; animal experiment; animal model; cytotoxicity; in vitro study; cancer inhibition; nude mouse; oncolytic virus; vaccinia virus; virus replication; flank; human; female; priority journal; article; viral plaque assay
Journal Title: Surgery
Volume: 158
Issue: 2
ISSN: 0039-6060
Publisher: Elsevier Inc.  
Date Published: 2015-08-01
Start Page: 331
End Page: 338
Language: English
DOI: 10.1016/j.surg.2015.03.044
PROVIDER: scopus
PUBMED: 26049609
PMCID: PMC4819004
DOI/URL:
Notes: Export Date: 2 September 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Justin William Ady
    10 Ady
  2. Laurence Justin Belin
    13 Belin